BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 35880755)

  • 1. Discovery of an Orally Bioavailable and Selective PKMYT1 Inhibitor, RP-6306.
    Szychowski J; Papp R; Dietrich E; Liu B; Vallée F; Leclaire ME; Fourtounis J; Martino G; Perryman AL; Pau V; Yin SY; Mader P; Roulston A; Truchon JF; Marshall CG; Diallo M; Duffy NM; Stocco R; Godbout C; Bonneau-Fortin A; Kryczka R; Bhaskaran V; Mao D; Orlicky S; Beaulieu P; Turcotte P; Kurinov I; Sicheri F; Mamane Y; Gallant M; Black WC
    J Med Chem; 2022 Aug; 65(15):10251-10284. PubMed ID: 35880755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition.
    Gallo D; Young JTF; Fourtounis J; Martino G; Álvarez-Quilón A; Bernier C; Duffy NM; Papp R; Roulston A; Stocco R; Szychowski J; Veloso A; Alam H; Baruah PS; Fortin AB; Bowlan J; Chaudhary N; Desjardins J; Dietrich E; Fournier S; Fugère-Desjardins C; Goullet de Rugy T; Leclaire ME; Liu B; Bhaskaran V; Mamane Y; Melo H; Nicolas O; Singhania A; Szilard RK; Tkáč J; Yin SY; Morris SJ; Zinda M; Marshall CG; Durocher D
    Nature; 2022 Apr; 604(7907):749-756. PubMed ID: 35444283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PKMYT1: A Potential Target for CCNE1 Amplificated Colorectal Tumors.
    Fang Y; Zhang X; Guo Y; Dong Y; Liu W; Hu X; Li X; Gao D
    Cell Biochem Biophys; 2023 Sep; 81(3):569-576. PubMed ID: 37572218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy.
    Guertin AD; Li J; Liu Y; Hurd MS; Schuller AG; Long B; Hirsch HA; Feldman I; Benita Y; Toniatti C; Zawel L; Fawell SE; Gilliland DG; Shumway SD
    Mol Cancer Ther; 2013 Aug; 12(8):1442-52. PubMed ID: 23699655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of PKMYT1 inhibitors by screening the GSK published protein kinase inhibitor set I and II.
    Platzer C; Najjar A; Rohe A; Erdmann F; Sippl W; Schmidt M
    Bioorg Med Chem; 2018 Aug; 26(14):4014-4024. PubMed ID: 29941193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting
    Xu H; George E; Gallo D; Medvedev S; Wang X; Kryczka R; Hyer ML; Fourtounis J; Stocco R; Aguado-Fraile E; Petrone A; Yin SY; Shiwram A; Anderson M; Kim H; Liu F; Marshall CG; Simpkins F
    Res Sq; 2024 Feb; ():. PubMed ID: 38410486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PKMYT1 is associated with prostate cancer malignancy and may serve as a therapeutic target.
    Wang J; Wang L; Chen S; Peng H; Xiao L; E Du ; Liu Y; Lin D; Wang Y; Xu Y; Yang K
    Gene; 2020 Jun; 744():144608. PubMed ID: 32234541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target.
    Ghelli Luserna di Rorà A; Cerchione C; Martinelli G; Simonetti G
    J Hematol Oncol; 2020 Sep; 13(1):126. PubMed ID: 32958072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Computer-aided design, synthesis and biological characterization of novel inhibitors for PKMYT1.
    Najjar A; Platzer C; Luft A; Aßmann CA; Elghazawy NH; Erdmann F; Sippl W; Schmidt M
    Eur J Med Chem; 2019 Jan; 161():479-492. PubMed ID: 30388464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BLM germline and somatic PKMYT1 and AHCY mutations: Genetic variations beyond MYCN and prognosis in neuroblastoma.
    Novak EM; Halley NS; Gimenez TM; Rangel-Santos A; Azambuja AM; Brumatti M; Pereira PL; Vince CS; Giorgi RR; Bendit I; Cristofani LM; Odone-Filho V
    Med Hypotheses; 2016 Dec; 97():22-25. PubMed ID: 27876123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PKMYT1 inhibits lung adenocarcinoma progression by abrogating AKT1 activity.
    Wang S; Liu X; Zhou T; Li J; Lin Y; Zhou A; Huang J; Zhao J; Cai J; Cai X; Huang Y; Li X
    Cell Oncol (Dordr); 2023 Feb; 46(1):195-209. PubMed ID: 36350496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protein kinase, membrane‑associated tyrosine/threonine 1 is associated with the progression of colorectal cancer.
    Jeong D; Kim H; Kim D; Ban S; Oh S; Ji S; Kang D; Lee H; Ahn TS; Kim HJ; Bae SB; Lee MS; Kim CJ; Kwon HY; Baek MJ
    Oncol Rep; 2018 Jun; 39(6):2829-2836. PubMed ID: 29658598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CCNE1 Amplification and PKMYT1 Inhibition Are Synthetic Lethal.
    Cancer Discov; 2022 Jul; 12(7):OF12. PubMed ID: 35522064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of MCRS1 on proliferation, migration, invasion, and epithelial mesenchymal transition of gastric cancer cells by interacting with Pkmyt1 protein kinase.
    Wang XM; Li QY; Ren LL; Liu YM; Wang TS; Mu TC; Fu S; Liu C; Xiao JY
    Cell Signal; 2019 Jul; 59():171-181. PubMed ID: 30953699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Knockdown of PKMYT1 is associated with autophagy inhibition and apoptosis induction and suppresses tumor progression in hepatocellular carcinoma.
    Wu F; Tu C; Zhang K; Che H; Lin Q; Li Z; Zhou Q; Tang B; Yang Y; Chen M; Shao C
    Biochem Biophys Res Commun; 2023 Jan; 640():173-182. PubMed ID: 36512849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PKMYT1 induced by YAP/TEAD1 gives rise to the progression and worse prognosis of bladder cancer.
    Wang M; Zhang C; Ying Y; Hua M; Meng F; Wang Z; Liu A; Zeng S; Zhang Z; Xu C
    Mol Carcinog; 2024 Jan; 63(1):160-172. PubMed ID: 37787394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ELF3 promotes gemcitabine resistance through PKMYT1/CDK1 signaling pathway in gallbladder cancer.
    Yang L; Wang H; Guo M; He M; Zhang W; Zhan M; Liu Y
    Cell Oncol (Dordr); 2023 Aug; 46(4):1085-1095. PubMed ID: 36988891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of PKMYT1 indicates the poor prognosis and enhances proliferation and tumorigenesis in non-small cell lung cancer via activation of Notch signal pathway.
    Sun QS; Luo M; Zhao HM; Sun H
    Eur Rev Med Pharmacol Sci; 2019 May; 23(10):4210-4219. PubMed ID: 31173292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic expression analysis of WEE family kinases reveals the importance of PKMYT1 in breast carcinogenesis.
    Liu Y; Qi J; Dou Z; Hu J; Lu L; Dai H; Wang H; Yang W
    Cell Prolif; 2020 Feb; 53(2):e12741. PubMed ID: 31837068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LncRNA PKMYT1AR promotes cancer stem cell maintenance in non-small cell lung cancer via activating Wnt signaling pathway.
    He Y; Jiang X; Duan L; Xiong Q; Yuan Y; Liu P; Jiang L; Shen Q; Zhao S; Yang C; Chen Y
    Mol Cancer; 2021 Dec; 20(1):156. PubMed ID: 34856993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.